Copanlisib

From WikiMD

Information about Copanlisib

Copanlisib is an intravenously administered phosphatidylinositol-3 kinase inhibitor that is used to treat relapsed and refractory follicular lymphoma.  

Liver safety of Copanlisib

Copanlisib is associated with a high rate of minor serum enzyme elevations during therapy and has been reported to cause clinically apparent acute liver injury that can be severe and even fatal. 

Mechanism of action of Copanlisib

Copanlisib (koe" pan lis' ib) is an intravenously administered small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) alpha and delta which are essential components in B cell signaling pathways that drive survival of B cells and their migration to lymph nodes and bone marrow.  Inhibition of this pathway inhibits B cell chemotaxis and adherence and reduces cell viability.  This pathway is upregulated in many B cell malignancies and is known to be critical for proliferation and survival of leukemia and lymphomatous malignant B lymphocytes. 

FDA approval information for Copanlisib

Copanlisib has been shown to result in high rates of objective response in patients with refractory or relapsed follicular lymphoma and was given accelerated approval for this use in the United States in 2017. 

Dosage and administration for Copanlisib

Copanlisib is available in as lyophilized powder in 60 mg single dose vials under the brand name Aliqopa.  The recommended dose is 60 mg given as an intravenous infusion on days 1, 8 and 15 of 28-day cycles. 

Side effects of Copanlisib

Side effects are common but usually mild-to-moderate in severity, and include nausea, diarrhea, headache, stomatitis, fever, pain, rash, infections, arthralgia and fatigue.  Common laboratory abnormalities can include hyperglycemia and cytopenias.  Severe adverse events can include marked hypertension, severe diarrhea, neutropenia, infectious and non-infectious pneumonitis, severe cutaneous reactions and embryo-fetal toxicity.

 


The article on Copanlisib is a stub. YOU can help Wikimd by expanding it!

Medication resources

Learn more


edit 

About WikiMD

About us: WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.

Our mission: Provide up to date physician reviewed health, nutrition and wellness information for free in over 100 languages.

Join us: This article is a stub. Help improve Copanlisib or others. Do not trust amateurs with your life! Join us in this effort!. Paid editors welcome.

Pubmed.png Uptodate.png Wikipedia Reddit YouTube videos
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="http://www.wikimd.org/wiki/Copanlisib">Copanlisib</a>

  • Individual results may vary for weight loss from our sponsors.